Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 16 February 2017 | By Michael Mezher
The Clinical Trials Transformation Initiative (CTTI) has released a set of recommendations it says will improve the use of antibiotics in children.
According to CTTI, a public-private partnership aimed at improving the quality and efficacy of clinical trials, challenges in enrolling and completing pediatric clinical trials for antibiotics leads to a situation where such drugs are used in children despite lacking adequate labeling for pediatric populations.
Furthermore, CTTI says that in many cases, pediatric labeling often comes five or more years after new antibiotics are approved for adult populations.
Specifically, CTTI recommends drugmakers take action to improve pediatric antibiotic use by proactively engaging with regulators and making study design considerations early on in drug development.
First, CTTI says drugmakers should align their studies with international regulators, such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), in order to support coordinated submissions across different regions.
As early as possible, CTTI says drugmakers should get input from FDA on their initial pediatric investigation plan as early as during adult Phase II trials.
Additionally, CTTI says drugmakers should consider conducting pediatric pharmacokinetic (PK) studies in children "concurrently with adult Phase III trials when appropriate."
Other recommendations include considerations for protocol designs to minimize the burden of the studies for pediatric patients and neonates, broadening eligibility criteria for pediatric studies and providing trial site staff with additional training on informed consent practices for such studies.
CTTI
Tags: Pediatric clinical trials, Antibacterial, Antibiotics, CTTI, Clinical Trials Transformation Initiative
Regulatory Focus newsletters
All the biggest regulatory news and happenings.